Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
| Autor: | H. Engler, D. Köberle, Walter F. Riesen, Markus Joerger, A. Templeton, Beat Thürlimann |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Randomization Bone disease Visual analogue scale Pain Pamidronate Antineoplastic Agents Bone Neoplasms Osteolysis Toxicology Gastroenterology Bone and Bones Collagen Type I Double-Blind Method N-terminal telopeptide Predictive Value of Tests Internal medicine Humans Medicine Pharmacology (medical) Prospective Studies Prospective cohort study Aged Pharmacology Diphosphonates business.industry Pamidronic acid medicine.disease Peptide Fragments Surgery Oncology Predictive value of tests Female business Cancer pain Biomarkers Procollagen medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 67:1137-1144 |
| ISSN: | 1432-0843 0344-5704 |
| DOI: | 10.1007/s00280-010-1420-z |
| Popis: | There is an urgent need for individualized treatment of malignant bone disease (MBD), as the clinical benefit from bone-targeted therapies is moderate. We assessed the predictive value of the bone formation marker procollagen type I N-propeptide (PINP) for skeletal morbidity in patients with MBD receiving pamidronate. Seventy patients with advanced MBD were randomized to receive pamidronate 60 mg (n = 35) or 90 mg (n = 35) every 3 weeks for six cycles in a double-blind study. PINP was analyzed at baseline and before each administration of pamidronate, using a validated ELISA. Serum PINP concentrations were compared with pain response (visual analog scale VAS, composite pain score) and skeletal morbidity (skeletal-related events, SRE) using Student’s T-test, Wilcoxon rank-sum and log-rank test, respectively. Patients with ≥20% pain reduction in the VAS had lower baseline PINP concentrations when compared to patients with |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink